GlassScriptPhysician profile
John S Dirksen
NPI 1679570147
$2,951.55
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $460 · 2021: $852 · 2022: $676 · 2023: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.54 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Alkermes, INC. | $259.01 | 2021-2023 | Lybalvi |
| Allergan, INC. | $251.99 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $224.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.33 | 2019-2022 | |
| Bausch Health US, LLC | $161.62 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.08 | 2020-2023 | |
| Adlon Therapeutics L.P. | $124.17 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $101.38 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $85.48 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $76.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $72.10 | 2019-2021 | |
| Neos Therapeutics, LP | $65.06 | 2020-2021 | |
| Brainsway USA INC | $37.88 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.86 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $34.85 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $34.42 | 2023 | Qelbree |
| Tris Pharma INC | $34.10 | 2022-2023 | Dyanavel Xr |
| Lundbeck LLC | $33.98 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $32.89 | 2019 | |
| Merck Sharp & Dohme LLC | $29.29 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.38 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.34 | 2019 | |
| Aytu Biopharma, INC. | $16.25 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.85 | 2019 | |
| Eisai INC. | $12.58 | 2020 | |
| Neuronetics, INC. | $4.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dirksen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.